Stifel Financial Corp Increases Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Stifel Financial Corp boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 7.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 48,245 shares of the biopharmaceutical company's stock after purchasing an additional 3,271 shares during the period. Stifel Financial Corp's holdings in Regeneron Pharmaceuticals were worth $50,717,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in REGN. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 19 shares during the period. Stephens Consulting LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $26,000. Sachetta LLC grew its stake in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 10 shares during the period. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $26,000. Finally, Family Firm Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $33,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 1.3 %

Regeneron Pharmaceuticals stock traded up $10.10 during mid-day trading on Friday, reaching $778.00. 813,640 shares of the company's stock were exchanged, compared to its average volume of 785,952. The company has a market cap of $85.49 billion, a P/E ratio of 19.25, a P/E/G ratio of 2.91 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a twelve month low of $735.95 and a twelve month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a fifty day moving average of $876.85 and a 200-day moving average of $1,011.68.

Analysts Set New Price Targets

Several research firms have recently weighed in on REGN. Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 price target for the company. Barclays dropped their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. StockNews.com lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday, November 4th. BMO Capital Markets decreased their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating on the stock in a report on Friday, November 1st. Finally, Oppenheimer decreased their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating on the stock in a report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $1,107.29.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.